By Josh Beckerman
Precigen received Food and Drug Administration approval of its lead product candidate, a drug for treatment of adults with recurrent respiratory papillomatosis.
The drug, which had been known as PRGN-2012, is now called Papzimeos.
Recurrent respiratory papillomatosis, caused by persistent human papillomavirus infection, leads to the growth of benign tumors in the respiratory tract, generally in the larynx.
In February, the FDA granted priority review, with a Prescription Drug User Fee Act target action date of Aug. 27.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 14, 2025 19:21 ET (23:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。